Advances in chimeric antigen receptor T cells therapy in the treatment of breast cancer

Qingjie He; Haibo Hu; Fan Yang; Dong Song; Xiaoling Zhang; Xiangpeng Dai

doi:10.1016/j.biopha.2023.114609

Advances in chimeric antigen receptor T cells therapy in the treatment of breast cancer

Biomed Pharmacother. 2023 Jun:162:114609. doi: 10.1016/j.biopha.2023.114609. Epub 2023 Mar 29.

Authors

Qingjie He¹, Haibo Hu², Fan Yang¹, Dong Song³, Xiaoling Zhang⁴, Xiangpeng Dai⁵

Affiliations

¹ Breast Surgery Department of General Surgery, The First Hospital of Jilin University, Changchun, China; Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, First Hospital of Jilin University, Changchun, China; National-Local Joint Engineering Laboratory of Animal Models for Human Disease, First Hospital of Jilin University, Changchun, China.
² Department of Cardiothoracic Surgery, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, Jiangsu, China.
³ Breast Surgery Department of General Surgery, The First Hospital of Jilin University, Changchun, China. Electronic address: songdong@jlu.edu.cn.
⁴ Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, First Hospital of Jilin University, Changchun, China; National-Local Joint Engineering Laboratory of Animal Models for Human Disease, First Hospital of Jilin University, Changchun, China. Electronic address: xiaolingzhang@jlu.edu.cn.
⁵ Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, First Hospital of Jilin University, Changchun, China; National-Local Joint Engineering Laboratory of Animal Models for Human Disease, First Hospital of Jilin University, Changchun, China. Electronic address: daixiangpeng@jlu.edu.cn.

PMID: 37001182
DOI: 10.1016/j.biopha.2023.114609

Abstract

Breast cancer (BC) is the most frequently occurring cancer type seriously threatening the lives of women worldwide. Clinically, the high frequency of diverse resistance to current therapeutic strategies advocates a demand to develop novel and effective approaches for the efficient treatment of BC. The chimeric antigen receptor T (CAR-T) cells therapy, one of the immunotherapies, has displayed powerful capacity to specifically kill and eliminate tumors. Due to the success of CAR-T therapy achieved in treating hematological malignancy, the effect of CAR-T cells therapy has been tested in various human diseases including breast cancer. This review summarized and discussed the landscape of the CAR-T therapy for breast cancer, including the advances, challenge and countermeasure of CAR-T therapy in research and clinical application. The roles of potential antigen targets, tumor microenvironment, immune escape in regulating CAR-T therapy, the combination of CAR-T therapy with other therapeutic strategies to further enhance therapeutic efficacy of CAR-T treatment were also highlighted. Therefore, our review provided a comprehensive understanding of CAR-T cell therapy in breast cancer which will awake huge interests for future in-depth investigation of CAR-T based therapy in cancer treatment.

Keywords: Breast cancer; CAR-T cell; Combined therapy; Immunotherapy; Tumor microenvironment.

Publication types

Review

MeSH terms

Breast Neoplasms* / drug therapy
Female
Humans
Immunotherapy, Adoptive
Neoplasms* / drug therapy
Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen*
T-Lymphocytes
Tumor Microenvironment

Substances

Receptors, Chimeric Antigen
Receptors, Antigen, T-Cell